- Home
- ANSS vs ILMN Comparison
ANSS vs ILMN Comparison
Compare ANSS & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANSS
- ILMN
- Stock Information
- Founded
- ANSS 1970
- ILMN 1998
- Country
- ANSS United States
- ILMN United States
- Employees
- ANSS N/A
- ILMN N/A
- Industry
- ANSS Computer Software: Prepackaged Software
- ILMN Medical Specialities
- Sector
- ANSS Technology
- ILMN Health Care
- Exchange
- ANSS Nasdaq
- ILMN Nasdaq
- Market Cap
- ANSS 27.8B
- ILMN 23.6B
- IPO Year
- ANSS 1996
- ILMN 2000
- Fundamental
- Price
- ANSS $342.84
- ILMN $135.21
- Analyst Decision
- ANSS Hold
- ILMN Buy
- Analyst Count
- ANSS 6
- ILMN 17
- Target Price
- ANSS $342.50
- ILMN $163.12
- AVG Volume (30 Days)
- ANSS 532.3K
- ILMN 2.3M
- Earning Date
- ANSS 02-19-2025
- ILMN 02-06-2025
- Dividend Yield
- ANSS N/A
- ILMN N/A
- EPS Growth
- ANSS 17.14
- ILMN N/A
- EPS
- ANSS 6.48
- ILMN N/A
- Revenue
- ANSS $2,467,743,000.00
- ILMN $4,390,000,000.00
- Revenue This Year
- ANSS $13.17
- ILMN N/A
- Revenue Next Year
- ANSS $9.54
- ILMN $4.05
- P/E Ratio
- ANSS $52.90
- ILMN N/A
- Revenue Growth
- ANSS 14.30
- ILMN N/A
- 52 Week Low
- ANSS $289.82
- ILMN $97.36
- 52 Week High
- ANSS $364.31
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- ANSS 51.88
- ILMN 40.42
- Support Level
- ANSS $331.47
- ILMN $130.31
- Resistance Level
- ANSS $344.81
- ILMN $137.69
- Average True Range (ATR)
- ANSS 6.51
- ILMN 5.31
- MACD
- ANSS -1.03
- ILMN -1.10
- Stochastic Oscillator
- ANSS 47.89
- ILMN 22.85
About ANSS ANSYS Inc.
Ansys is an engineering software company that provides simulation capabilities for structural, fluids, semiconductor power, embedded software, optical, and electromagnetic properties. Ansys employs over 4,000 people and serves over 50,000 customers globally, including those in aerospace defense and automotive.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.